688180:SSEShanghai Junshi Biosciences Co., Ltd. Class A Analysis
Data as of 2026-09-13 - not real-time
CN¥31.14
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
At ¥31.14, Shanghai Junshi Biosciences Co., Ltd. shows no decisive moving-average alignment, leaving the trend neutral. The last 30 days have lost 14.7%. Relative strength is 33.4 — approaching oversold — and the MACD signal is bearish. Watch ¥30.71 as support and ¥41.42 as the nearer resistance level.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Analyst price targets sit 10.1% below the current price. Revenue is growing at 45.2% on a -14.6% profit margin.
Risk comes out at 6 of a possible 10, a elevated reading. With 30-day volatility of 54.2%, a beta of 0.77 and a maximum drawdown of 40.7%, position sizing matters here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Short, medium and long-term reads agree on sell, with conviction of 6/10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Analyst price targets sit 10.1% below the current price. Revenue is growing at 45.2% on a -14.6% profit margin.
Risk comes out at 6 of a possible 10, a elevated reading. With 30-day volatility of 54.2%, a beta of 0.77 and a maximum drawdown of 40.7%, position sizing matters here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Short, medium and long-term reads agree on sell, with conviction of 6/10.
Top Market Events
SHANGHAI, April 20, 2026 GLOBE NEWSWIRE -- Shanghai Junshi Biosciences Co.Yahoo Finance1monJunshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus...Yahoo Finance3monJunshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for...
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 6/10
Key Factors
- Trading below the 200-day average of 35.82
- MACD momentum is negative
- 30-day price change of -14.7%
Medium Term
1–3 yearsCautious
Model confidence: 6/10
Key Factors
- Trading below the 200-day average of 35.82
- Analyst targets imply -10.1% versus the current price
- 30-day volatility of 54.2%
Long Term
> 3 yearsCautious
Model confidence: 6/10
Key Factors
- Negative profit margin of -14.6%
- Analyst targets imply -10.1% versus the current price
- Negative return on equity of -9.3%
Key Metrics & Analysis
Financial Health
Revenue Growth45.20%
Profit Margin-14.57%
P/E Ratio-112.0
ROE-9.32%
ROA-2.26%
Debt/Equity96.14
P/B Ratio5.4
Op. Cash FlowCN¥-258741632
Free Cash FlowCN¥-856972032
Industry P/E29.5
Technical Analysis
TrendNeutral
RSI33.4
SupportCN¥30.71
ResistanceCN¥41.42
MA 20CN¥34.79
MA 50CN¥36.28
MA 200CN¥35.82
MACDBearish
VolumeDecreasing
Fear & Greed Index93.14
Valuation
Target PriceCN¥28.00
Upside/Downside-10.08%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.77
Volatility54.20%
Sector RiskMedium
Reg. RiskHigh
Geo RiskHigh
Currency RiskHigh
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.